STEP THERAPY CRITERIA

This list is current as of 11/01/2019 and pertains to the following formularies:

| 2020 Independent Health’s Medicare Advantage C-SNP Part D Formulary | Version 9 |

In some cases, we require that you first try certain drugs to treat your medical condition before we will cover another drug for that condition. For example, if Drug A and Drug B both treat your medical condition, we may not cover Drug B unless you try Drug A first. If Drug A does not work for you, we will then cover Drug B. This document contains the Step Therapy protocols that are associated with our Medicare Advantage Part D Formularies.

If you have any questions, please contact our Medicare Member Services Department at 1-800-665-1502 or, for TTY users 711, October 1st – March 31st: Monday through Sunday from 8 a.m. to 8 p.m., April 1st – September 30th: Monday through Friday from 8 a.m. to 8 p.m.

The formulary may change at any time. You will receive notice when necessary.
Aliskiren Step

Products Affected

- *aliskiren fumarate tablet 150 mg oral*
- *aliskiren fumarate tablet 300 mg oral*
- *TEKTURNA HCT TABLET 150-12.5 MG ORAL*
- *TEKTURNA HCT TABLET 150-25 MG ORAL*
- *TEKTURNA HCT TABLET 300-12.5 MG ORAL*
- *TEKTURNA HCT TABLET 300-25 MG ORAL*

Details

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior prescription history of an ARB to obtain any products containing aliskiren.</td>
<td></td>
</tr>
</tbody>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Doxercalciferol Step

## Products Affected
- *doxercalciferol capsule 0.5 mcg oral*
- *doxercalciferol capsule 1 mcg oral*
- *doxercalciferol capsule 2.5 mcg oral*

## Details

| Criteria | Prior prescription history includes past use of calcitriol. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
## Eucrisa Step

### Products Affected
- **EUCRISA OINTMENT 2 % EXTERNAL**

### Details

| Criteria | Prior prescription history positive for the use of either a topical corticosteroid or topical calcineurin inhibitor. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# GLP-1 Step

## Products Affected

- BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS
- BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS
- BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS
- BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML
- OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS
- TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS
- VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS

## Details

| Criteria | Prior prescription history includes concurrent use of metformin, a sulfonylurea, a DPP-4 inhibitor, a TZD, or an SGLT-2 inhibitor before a GLP-1 agonist. Step therapy does not apply when written by endocrinologist. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Mirvaso Step

## Products Affected
- MIRVASO GEL 0.33 % EXTERNAL

## Details

| Criteria | Prior prescription history positive for the use of azelaic acid. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Paricalcitol/Rayaldee Step

Products Affected

- paricalcitol capsule 1 mcg oral
- paricalcitol capsule 2 mcg oral
- paricalcitol capsule 4 mcg oral
- RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORAL

Details

<table>
<thead>
<tr>
<th>Criteria</th>
</tr>
</thead>
<tbody>
<tr>
<td>Prior prescription history includes past use of calcitriol.</td>
</tr>
</tbody>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
Perforomist Step

Products Affected
• PERFOROMIST NEBULIZATION SOLUTION 20 MCG/2ML INHALATION

Details

| Criteria                                      | Prior prescription history positive for the use of Brovana. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
# Rocklatan Step

## Products Affected
- ROCKLATAN SOLUTION 0.02-0.005 % OPHTHALMIC

## Details

| Criteria | Prior prescription history positive for the use of an ophthalmic prostaglandin inhibitor. |

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
### Tramadol ER Biphasic Step

**Products Affected**
- tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral
- tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral
- tramadol hcl er capsule extended release 24 hour 150 mg oral
- tramadol hcl er capsule extended release 24 hour 200 mg oral
- tramadol hcl er capsule extended release 24 hour 300 mg oral

**Details**

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Requires the use of an immediate-release tramadol product or non-biphasic extended-release tramadol first.</th>
</tr>
</thead>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
## Uloric Step

### Products Affected
- *febuxostat tablet 40 mg oral*
- *febuxostat tablet 80 mg oral*

### Details

<table>
<thead>
<tr>
<th>Criteria</th>
<th>Requires the use of allopurinol first.</th>
</tr>
</thead>
</table>

You can find information on what the symbols and abbreviations on this table mean by going to page VI.
INDEX

calisken fumarate tablet 150 mg oral ........ 1
calisken fumarate tablet 300 mg oral ........ 1
BYDUREON BCISE AUTO-INJECTOR 2 MG/0.85ML SUBCUTANEOUS ............ 4
BYDUREON PEN-INJECTOR 2 MG SUBCUTANEOUS .............................. 4
BYETTA 10 MCG PEN SOLUTION PEN-INJECTOR 10 MCG/0.04ML SUBCUTANEOUS ............................. 4
BYETTA 5 MCG PEN SOLUTION PEN-INJECTOR 5 MCG/0.02ML SUBCUTANEOUS .................. 4
doxercalciferol capsule 0.5 mcg oral .................. 2
doxercalciferol capsule 1 mcg oral .................. 2
doxercalciferol capsule 2.5 mcg oral .................. 2
EUCRISA OINTMENT 2 % EXTERNAL .................. 3
febuxostat tablet 40 mg oral ....................... 10
febuxostat tablet 80 mg oral ....................... 10
MIRVASO GEL 0.33 % EXTERNAL ................... 5
OZEMPIC (0.25 OR 0.5 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS ............................................. 4
OZEMPIC (1 MG/DOSE) SOLUTION PEN-INJECTOR 2 MG/1.5ML SUBCUTANEOUS .................. 4
paricalcitol capsule 1 mcg oral ..................... 6
paricalcitol capsule 2 mcg oral ..................... 6
paricalcitol capsule 4 mcg oral ..................... 6
PERFOROMIST NEBULIZATION SOLUTION 20 MCG/2ML INHALATION .................. 7
RAYALDEE CAPSULE EXTENDED RELEASE 30 MCG ORAL ................................. 6
ROCKLATAN SOLUTION 0.02-0.005 % OPHTHALMIC ........................................ 8
TEKTURNA HCT TABLET 150-12.5 MG ORAL .... 1
TEKTURNA HCT TABLET 150-25 MG ORAL .... 1
TEKTURNA HCT TABLET 300-12.5 MG ORAL .... 1
TEKTURNA HCT TABLET 300-25 MG ORAL .... 1
tramadol hcl er (biphasic) tablet extended release 24 hour 100 mg oral ............... 9
tramadol hcl er (biphasic) tablet extended release 24 hour 200 mg oral ............... 9
tramadol hcl er (biphasic) tablet extended release 24 hour 300 mg oral ............... 9

tramadol hcl er capsule extended release 24 hour 100 mg oral .................. 9
tramadol hcl er capsule extended release 24 hour 150 mg oral .................. 9
tramadol hcl er capsule extended release 24 hour 200 mg oral .................. 9
tramadol hcl er capsule extended release 24 hour 300 mg oral .................. 9
TRULICITY SOLUTION PEN-INJECTOR 0.75 MG/0.5ML SUBCUTANEOUS .................. 4
TRULICITY SOLUTION PEN-INJECTOR 1.5 MG/0.5ML SUBCUTANEOUS .................. 4
VICTOZA SOLUTION PEN-INJECTOR 18 MG/3ML SUBCUTANEOUS .................. 4